Elicio Therapeutics (ELTX) Non-Current Debt (2020 - 2026)

Elicio Therapeutics has reported Non-Current Debt for 4 years, with the latest figure at $9.5 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Debt changed N/A year-over-year to $9.5 million; the trailing twelve-month figure through Mar 2026 stood at $9.5 million (changed N/A YoY), and the FY2025 full-year result was $9.4 million, down 53.04% from the prior year.
• Non-Current Debt for Q1 2026 stood at $9.5 million, up from $9.4 million in the prior quarter.
• The five-year high for Non-Current Debt was $20.0 million in Q4 2024, with the low at $9.3 million in Q2 2025.
• Historically, Non-Current Debt has averaged $11.6 million across 3 years, with a median of $9.5 million in 2026.
• The largest YoY upside for Non-Current Debt was 53.04% in 2025 against a maximum downside of 53.04% in 2025.
• Elicio Therapeutics' Non-Current Debt stood at $20.0 million in 2024, then tumbled by 53.04% to $9.4 million in 2025, then rose by 0.72% to $9.5 million in 2026.
• The last three Non-Current Debt figures came in at $9.5 million (Q1 2026), $9.4 million (Q4 2025), and $9.7 million (Q3 2025), per Business Quant data.